Tobin L. Brown, RN, BScN, ACRN March 16, 2012
|
|
- Ralph Hall
- 5 years ago
- Views:
Transcription
1 Tobin L. Brown, RN, BScN, ACRN March 16, 2012
2 New treatment guidelines New medications PrEP update Research findings Aging
3 Mathematical calculation, like pack years for smoking created by AIDS Research Network of Integrated Clinical Systems to draw associated between viral copy years and mortality. Bottom line: greater exposure to HIV virus over time is an independent predictor of death Supports ideas that viremia is harmful even when CD4 count is >200 Effects of viremia, immune activation and inflamation can be proven
4 Initiate ARV s if CD4 < 350, recommend treatment start when CD4 between Initiate treatment, regardless of CD4 if: HIV associated neuropathy, and HBV coinfection Treatment of all HIV + pregnant women with the goal to prevent perinatal transmission Panel on Antiviral Guidelines for Adults and Adolescents. Guidelines for the use of antretroviral agents in HIV-1- infected adults and adolescents. Department of Health and Human Services. October 14, 2011.
5 Complera: ripliverine 25 mg/emtricitabine 200 mg/ tenofovir 300 mg Comparable to sustiva- Fewer neuro side effects
6 No longer requires refrigeration Will be automatically substituted by pharmacy now that finally approved by ODB Should reduce further GI complications To be taken with food
7 Raltegravir 400 mg twice daily plus Truvada once daily -fewer drug interactions than most PI s -more lipid neutral
8 New Tenofovir pro-drug with superior drug efficacy The quad pill: Elivegravir (integrase), and new boosting agent cobicistat, Emtricitabine, and Tenofovir (or new pro-drug) New integrase inhibitor Dolutegravir for those with extensive drug resistance
9 FEM-PrEP: study halted April, 2011 due to similar infection rate in both FTC/3TC & placebo arm -Importance of adherence PARTNERS PrEP Study: 4700 HIV discordant couples Kenya/Uganda comparing 2 ARV/1ARVplacebo arm d/c and participants offered PrEP Points for discussion: cost, adherence requirement?
10 For use in confirmed HIV negative with regular HIV testing and assessment PrEP should only be taken by individuals for whom it has been ordered Not to be used in pregnant or breastfeeding women Must be taken DAILY!
11 2011 breakthrough of the year!! Demonstrated antiretrovial medication can treat as well as prevent transmission of HIV Ongoing since 2005 with >1700 heterosexual couples several African countries, Thailand, and US. (Slated to end 2015.) Independent review found 28 transmissions in the wait for treatment arm, and only 1 in the immediate treatment arm
12 When used with other prevention methods a great leap forward! Scale up proven prevention methods such as routine HIV testing, knowing HIV status, early treatment initiation, consistent condom use, clean needle exchange, adult male circumcision as indicated, PMTC transmission and eventually PrEP, microbicides and other female controlled prevention, preventative vaccine(s) Limitations of this study for application of findings to MSM and needle sharing individuals
13 University of Western Ontario announced development of a vaccine Approved by FDA to begin human clinical trials SAV001: genetically modified, inactivated whole virus Phase 1-begins Jan/12 30 HIV positive people safety Phase 2-examines immune responses in humans-approx 600 high risk HIV negative people Phase 3-determine efficacy of the vaccine-6000 HIV negative volunteers at high risk
14 Diligent monitoring of cardiovascular risk factors: BP, cholesterol Pro-active approach to healthcare colon cancer screening, updated vaccinations, bone density tests, PAP smears for women, age appropriate breast screening, vision and dental assessment, treatment of HCV/HBV as indicated, early and ongoing antiviral therapy, mental health services to address age related depression/cognition changes
15 Smoking is the single most important risk factor for lung cancer in HIV infected individuals. Equates to 14-fold increase in risk to develop lung cancer (no link between low CD4 and previous AIDS defining lung disease) Exercise, diet, ETOH, non-prescribed medications
16 Decreased serotonin levels, cardiovascular flow, endorphins Poor sleep hygiene Mental Health and HIV 50% more likely to have mental health issue than control
17
18
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationPrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.
PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationTRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers
TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication Training Guide for Healthcare Providers About TRUVADA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in high-risk
More informationThe role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationUsing PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination
Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More informationSuccessful results of clinical trials
Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected
More informationPEP, PREP, HPTN052 and MLN2238
PEP, PREP, HPTN052 and MLN2238 Understanding the alphabet soup of HIV prevention and cure strategies Christina G Rivera, PharmD, BCPS Pharmacy Grand Rounds August 15, 2017 2017 MFMER slide-1 Presentation
More informationHIV PREP THE NEWEST TOOL IN THE BOX
HIV PREP THE NEWEST TOOL IN THE BOX Infectious Disease Update November 7, 2014 Andrew Petroll, MD, MS Department of Medicine, Division of Infectious Diseases Department of Psychiatry and Behavioral Medicine,
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationPREVENTION OF HIV IN THE TIMES OF PREP. Daniela Chiriboga, MD Florida Department of Health in Polk County
PREVENTION OF HIV IN THE TIMES OF PREP Daniela Chiriboga, MD Florida Department of Health in Polk County MAKING THE CASE FOR PREVENTION The Epidemic in Florida Population in 2014: 19.6 million (3 rd in
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationAbout FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.
Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention
More informationKEEP LOVING. Because HIV doesn t change who you are.
KEEP LOVING. Because HIV doesn t change who you are. BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in certain adults. BIKTARVY does not cure HIV-1 or AIDS. Please
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationReportback from the 2013 ICAAC in Denver, CO
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p3 p8 PrEP NEWS New tenofovir vaginal ring protects monkeys, PrEP uptake higher among women and young people. HIV CARE
More informationCase year old single gay man First contact with clinic in Nov Unprotected sex 60 hours previously Received PEP Remained HIV-negative
PrEP Case Studies Case 1 62 year old single gay man First contact with clinic in Nov 2011 Unprotected sex 60 hours previously Received PEP Remained HIV-negative Repeat exposures requiring PEP in 2013,
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationInformation, inspiration and advocacy for people with HIV/AIDS and hepatitis C
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p5 p6 p7 HIV CARE NEWS New drugs: dolutegravir, MK-1439, cenicriviroc, and HIV and heart health. HIV PrEP NEWS Disappointing
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationAre you PrEP(ared)? PrEP Basics & Knowledge Dissemination
Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination Harlan Pruden Educator, Chee Mamuk, Aboriginal Program BC Center for Disease Control, Clinical Prevention Services Sḵwx on the traditional, ancestral
More informationReview of planned trials and key emerging issues for Thailand
Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom
More informationNew Guidelines Recommend. Maraviroc Approved for. Telaprevir Under Study. Highleyman CROI 2010
Liz Highleyman C O N F E R E N C E C O V E R A G E The 17 th Conference on Retroviruses and Opportunistic Infections (CROI), which took place February 16 19 in San Francisco, is one of the major annual
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationHIV & THE MEDICAL HOME A NEW FRONT FOR GETTING TO ZERO. Brent K. Sugimoto, MD, MPH Kaiser Permanente. 29th Annual East Bay HIV Update June 3, 2016
HIV & THE MEDICAL HOME A NEW FRONT FOR GETTING TO ZERO 29th Annual East Bay HIV Update June 3, 2016 Brent K. Sugimoto, MD, MPH Kaiser Permanente Photo Credit: C. GoldsmithContent Providers: CDC/ C. Goldsmith,
More informationPre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018
Pre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018 Disclosures I have no financial disclosures to report Objectives Identify the need for HIV prevention
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationSFAF CLINICAL PROTOCOLS
SFAF CLINICAL PROTOCOLS Page 1 of Supersedes Date: December 31, 2016 Original Date: August 20, 2014 Version: 03 Policy Section: Patient Care Non-Occupational Post Exposure Prophylaxis Program Back ground:
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationPrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine
PrEP and npep for HIV Prevention Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine Case Study A 26 y/o M presents for routine asymptomatic screening for sexually transmitted infections
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationAIDS 2012 Washington. Dr Edward Coughlan Clinical Director
AIDS 2012 Washington Dr Edward Coughlan Clinical Director Material contructed from notes From CCO AIDSMap/NAM The US was criticised for denying sex workers visas to enter the country and attend AIDS 2012.
More informationYou matter and so does your health.
DESCOVY is a prescription medicine that is used together with other HIV-1 medicines to treat HIV-1 in people who weigh at least 77 lbs (35kg). DESCOVY does not cure HIV-1 or AIDS. Do not use DESCOVY to
More informationHIV Reproductive Health: Conception Options in the Era of PrEP
HIV Reproductive Health: Conception Options in the Era of PrEP Meg Sullivan, MD Director, HIV Clinical Programs, Section of Infectious Diseases Boston Medical Center Boston University School of Medicine
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationPREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER
PREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER THE NEED FOR CONTINUED HIV PREVENTION Estimated new HIV infections in the US for the most
More informationPrEP 201: Beyond the Basics
NORTHWEST AIDS EDUCATION AND TRAINING CENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington February 19, 2015 Disclosures and Disclaimers I
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in
More informationPost-Sexual Exposure Prophylaxis (npep)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Post-Sexual Exposure Prophylaxis (npep) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More information2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,
More informationModule 7: Healthy Living
Module 7: Healthy Living Fitness to work The UN treats HIV as any other chronic disease. Regardless of your HIV status, you have the right to work and also not to be discriminated against in the workplace.
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationBiomedical HIV Prevention & TaP Treatment as Prevention 2013
Biomedical HIV Prevention & TaP Treatment as Prevention 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationduring conception, pregnancy and lactation at 2 U.S. medical centers
Use of HIV preexposure prophylaxis during conception, pregnancy and lactation at 2 U.S. medical centers Dominika Seidman, MD Shannon Weber, Maria Teresa Timoney, Karishma Oza, Elizabeth Mullins, Rodney
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationPrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?
PrEP Guidelines for the Ob/Gyn Megan J. Huchko, MD, MPH Obstetrics and Gynecology Update October 14, 2015 I have no financial or other conflicts of interest to declare Outline The Need for PrEP: HIV Treatment
More informationRecent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology HIV stands for human immunodeficiency virus. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).
More informationHIV / AIDS. Prevention In Our Lives
HIV / AIDS Prevention In Our Lives Prevention In Our Lives: Produced by the Treatment Action Campaign. Authors: Published: September 2010 Conte n t s Introduction: Statistics on HIV in South Africa 2 Why
More informationAn International Antiviral Society-USA
Doug Campos-Outcalt, MD, MPA University of Arizona, Phoenix dougco@email.arizona. edu A look at new guidelines for HIV treatment and prevention Start antiretroviral therapy as soon as possible after HIV
More informationPre-Exposure Prophylaxis (PrEP) for HIV Infection
Pre-Exposure Prophylaxis (PrEP) for HIV Infection Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More information